Sagimet Biosciences Inc.

NASDAQ:SGMT

Biotechnology

Healthcare
$10.11 +1.38%

+$0.09 today

Market cap
$711.15M
Beta
3.44
P/E (TTM)
-5.0
EPS (TTM)
-$1.34
52W Low $4.50High $11.41

Volume 0.93M

Average 1.49M

SGMT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Sagimet Biosciences Inc.NASDAQ: SGMT

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows in line with its trailing trend

Q1 FY2026 selling, general & admin of $4.72M rose 4.3% year over year, behind the +5.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 17.0% from the prior quarter. Over 3 fiscal years it compounded at +42.7% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of $232.92K (-98.7%) for the fiscal year ending Dec 2026, a slowdown from the +11.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.72M+17.0% QoQ
Last fiscal yearDec 2025
$17.84M+11.4% YoY
LTMMar 2026
$18.03M+5.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%-100.0%-104.3 pp
1 year+11.4%-98.7%-110.1 pp
3-year CAGR+42.7%+25.5%-17.2 pp
5-year CAGR+104.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
17.84M USD
Year-over-year change
+11.4%
4-year CAGR
+42.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How SGMT compares with its peers on the latest reported figures

  • SGMT's LTM Mar 2026 selling, general & admin of $18.03M is the lowest of the 11 companies compared; the peer median is $34.17M.
  • Its year-over-year change of +5.9% is the 4th highest of 11, against a peer median of -0.6%.
  • Over three fiscal years its annual growth of +42.7% compares with a peer median of +5.1%.
SGMT Competitors Peer median
Selling, General & Admin for SGMT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$4.7B +29505.3%+3.5%—
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M -11.6%+0.0%96.1%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$40.9M +4.0%+10.2%712.8%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$36.17M -2.1%+6.6%99.1%
ZURAZura Bio LimitedLTM Mar 2026$35.14M +1.0%+112.2%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$33.2M +76.0%+43.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M -34.0%-12.3%—
HUMAHumacyte, Inc.LTM Mar 2026$27.31M -10.2%+10.9%1354.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$26.89M -3.6%-3.6%95.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$19.78M +10.8%-6.4%27.8%
SGMTSagimet Biosciences Inc.LTM Mar 2026$18.03M +5.9%+42.7%—
Peer median (excluding SGMT) $34.17M-0.6%+5.1%97.6%

Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue002M00
Cost of Revenue00000
Gross Profit002M00
Gross Margin——100.0%——
Research & Development19.34M24.92M19.78M38.44M39.05M
Selling, General & Admin4.38M6.14M12.96M16.01M17.84M
Operating Expenses23.72M31.06M32.74M54.45M56.89M
Depreciation & Amortization0130K000
EBITDA(24.44M)(30.37M)(27.88M)(45.57M)(51.04M)
EBITDA Margin——-1393.8%——
Operating Income(23.72M)(31.06M)(30.74M)(54.45M)(56.89M)
Operating Margin——-1537.0%——
Interest Income26K553K2.86M8.89M5.85M
Interest Expense00000
Other Income / Expenses(723K)556K2.86M8.89M5.85M
Income Before Tax(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Pre-Tax Margin——-1393.8%——
Income Tax Expense00000
Net Income(24.44M)(30.5M)(27.88M)(45.57M)(51.04M)
Net Margin——-1393.8%——
EPS (Basic)(1.10)(1.38)(1.53)(1.45)(1.58)
EPS (Diluted)(1.10)(1.38)(1.53)(1.45)(1.58)
Weighted Avg Shares22.17M22.17M18.19M31.35M32.35M
Weighted Avg Shares (Diluted)22.17M22.17M18.19M31.35M32.35M

Sagimet Biosciences Inc.

NASDAQ:SGMT

Intrinsic Alpha fair value

Locked

Current Price

$10.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.